Patents by Inventor Jean-Francois Riou

Jean-Francois Riou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • POLY-HETEROARYL DERIVATIVES FOR THE TREATMENT OF CANCER
    Publication number: 20110201648
    Abstract: The present invention relates to Penta-hexa-, hepta-, octa-, nona- and, deca-heteroaryl derivatives, comprising a combination of heterocycle 1 (Het-1)a and/or heterocycle 2 (Het-2)b and/or heterocycle 3 (Het-3)c and/or heterocycle 4 (Het-4)d of formulae I, II, III and IV respectively, the N-oxides, the pharmaceutically acceptable addition salts. The compounds claimed are suitable for the treatment of cancer.
    Type: Application
    Filed: November 2, 2009
    Publication date: August 18, 2011
    Applicants: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), MUSEUM NATIONAL D'HISTOIRE NATURELLE (MNHN)
    Inventors: Chi-hung Nguyen, Myriam Rouchon Dagois, Aurore Guedin-Beaurepaire, David Monchaud, Marie-Paule Teulade-Fichou, Jean-François Riou, Jean-Louis Mergny, David Grierson
  • CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS
    Publication number: 20090226411
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: December 16, 2008
    Publication date: September 10, 2009
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patrick MAILLIET, Abdelazize LAOUI, Jean-Francois RIOU, Gilles DOERFLINGER, Jean-Louis MERGNY, Francois HAMY, Thomas CAULFIELD
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 7482352
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: January 27, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives as antitelomerase agents which bind specifically to the G-quadruplex DNA structures and their application as a specific anticancer agent
    Publication number: 20070232572
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds and their therapeutic application in humans.
    Type: Application
    Filed: February 6, 2004
    Publication date: October 4, 2007
    Applicants: Aventis Pharma S.A., Centre National De La Recherche Scientifique, Museum National D'Histoire Naturelle, Institut Curie, Commissariat A L'Energie Atomique, Universite De Reims Champagne-Ardenne
    Inventors: Augustin Hittinger, Thomas Caulfield, Patrick Mailliet, Herve Bouchard, Eliane Mandine, Jean-Louis Mergny, Lionel Guittat, Jean-Francois Riou, Dennis Gomez, Chafke Belmokhtar
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 7179816
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: February 20, 2007
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Triazine derivatives and their application as antitelomerase agents
    Patent number: 6887873
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: May 3, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-François Riou, Gilles Doerflinger, Jean-Louis Mergny, François Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20050070571
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: November 19, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdekazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20050070575
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 30, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 6858608
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: February 22, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-François Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Polypeptides capable of interacting with human topoisomerase III alpha
    Publication number: 20040152162
    Abstract: The invention concerns novel peptides capable of interacting with the human topoisomerase III&agr; and the nucleic acid sequences coding for said polypeptides. The invention also concerns a method for identifying compounds capable of interacting with said polypeptides and a method for identifying molecules capable of modulating the interaction of the topoisomerase III&agr; with said polypeptides.
    Type: Application
    Filed: January 29, 2004
    Publication date: August 5, 2004
    Applicant: Aventis Pharma S.A.
    Inventors: Alain Fournier, Helene Goulaouic, Jean-Francois Riou
  • Oxindoles which are inhibitors of CDK-1 and their application in therapeutics
    Publication number: 20040110770
    Abstract: The present invention relates to a compound of formula (I): 1
    Type: Application
    Filed: August 20, 2003
    Publication date: June 10, 2004
    Applicant: AVENTIS PHARMA SA
    Inventors: Jean-Francois Riou, Michel Maratrat, Lucile Grondard, Fabienne Thompson, Odile Petitgenet, Patrick Mailliet, Jacques Lavayre
  • Chemical derivatives and their application as antitelomerase agent
    Publication number: 20040053966
    Abstract: The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 10, 2003
    Publication date: March 18, 2004
    Applicant: Aventis Pharms S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Jean-Louis Mergny, Abdelazize Laoui, Francois Lavelle, Odile Petitgenet
  • Polypeptides capable of interacting with the human topoisomerase III&agr;
    Patent number: 6706514
    Abstract: The invention concerns novel polypeptides capable of interacting with the human topoisomerase III&agr; and the nucleic acid sequences coding for said polypeptides. The invention also concerns a method for identifying compounds capable of interacting with said polypeptides and a method for identifying molecules capable of modulating the interaction of the topoisomerase III&agr; with said polypeptides.
    Type: Grant
    Filed: June 25, 2001
    Date of Patent: March 16, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Alain Fournier, Hélène Goulaouic, Jean-Francois Riou
  • Chemical derivatives and their application as antitelomerase agent
    Patent number: 6645964
    Abstract: The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 11, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-François Riou, Jean-Louis Mergny, Abdelazize Laoui, François Lavelle, Odile Petitgenet
  • Chemical derivatives and their application as antitelomerease agent
    Publication number: 20030087931
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: March 25, 2002
    Publication date: May 8, 2003
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20030078263
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: January 9, 2002
    Publication date: April 24, 2003
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20030013711
    Abstract: The present invention relates to cancer therapies using novel anticancer agents with a specific mechanism of action. The invention also relates to novel chemical compounds and their therapeutic application in man.
    Type: Application
    Filed: February 22, 2002
    Publication date: January 16, 2003
    Inventors: Patrick Mailliet, Jean-Francois Riou, Abdelazize Laoui, Jean-Louis Mergny, Sylvie Gontier
  • Chemical derivatives and use thereof as antitelomerase agents
    Publication number: 20020103169
    Abstract: Novel anticancer agents of the phenanthridine class having a specific mechanism of action and cancer therapy methods are described, including the novel chemical compounds and their therapeutic use thereof in humans.
    Type: Application
    Filed: August 8, 2001
    Publication date: August 1, 2002
    Inventors: Patrick Mailliet, Jean-Francois Riou, Jean-Louis Mergny, Abdelazize Laoui
  • Compositions containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor and compositions containing at least one farnesyl transferase inhibitor and at least one taxoid
    Patent number: 6342487
    Abstract: Combinations containing at least one farnesyl transferase inhibitor and at least one topoisomerase inhibitor. Combinations containing at least one taxoid and at least one farnesyl transferase inhibitor.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: January 29, 2002
    Assignee: Aventis Pharma Rorer S.A.
    Inventors: Jean-François Riou, Patrick Mailliet, Patricia Vrignaud